Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on developing medicines for people with cancer. The Company is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma). Its eganelisib clinical development program includes MAcrophage Reprogramming in Immuno-Oncology-3 (MARIO-3), MARIO-275 and MARIO-1. MARIO-3 is a multi-arm Phase II study designed to evaluate eganelisib in the front-line treatment for both metastatic triple-negative breast cancer (TNBC), and renal cell carcinoma (RCC). MARIO-275 is its global, randomized, placebo-controlled Phase II study evaluating the effect of adding eganelisib to nivolumab, also known as Opdivo, in checkpoint-naive advanced urothelial cancer (UC). MARIO-1 is in the Phase I/Ib clinical study.

Employees

Sector

Environmental Services & Equipment

More about the company

Quotes

Date	Price	Change	Volume
10/26/10	0.000001 $	0.00%	4,100
05/26/05	0.000001 $	0.00%	22,250
04/26/04	0.000001 $	0.00%	400
03/26/03	0.000001 $	0.00%	1,000

End-of-day quote OTC Markets

More quotes

End-of-day quote OTC Markets Other stock markets 10/06/2026			5-day change	1st Jan Change
0.000001 ^USD	0.00%		0.00%	-

25/24/25	Infinity Pharmaceuticals, Inc. Went Out of Business	CI
07/24/07	Revised Liquidation Plan Approved for Infinity Pharmaceuticals, Inc.	CI

Market Cap	2L 2L 2L 2L 3L 2.17Cr 3L 21.65L 8L 1.05Cr 9L 8L 3.64Cr	P/E Ratio 2021	-4.25x	P/E Ratio 2022	-1.11x
Enterprise Value	1.13Cr 97.73L 90.09L 84.41L 1.58Cr 107.83Cr 1.61Cr 11Cr 4.16Cr 52Cr 4.23Cr 4.14Cr 180.73Cr	EV / Sales 2021	91.8x	EV / Sales 2022	23.4x
Free-Float	100%	Yield 2021 *	-	Yield 2022	-

25/24/25	Infinity Pharmaceuticals, Inc. Went Out of Business	CI
07/24/07	Revised Liquidation Plan Approved for Infinity Pharmaceuticals, Inc.	CI
22/24/22	Motion for Di Minimis Assets Sale Approved for Infinity Pharmaceuticals, Inc.	CI
15/24/15	An unknown healthcare investment firm acquired Substantially all of the assets of Infinity Pharmaceuticals, Inc. (OTCPK:INFI.Q).	CI
13/24/13	First Motion for Exclusivity Period Extension Approved For Infinity Pharmaceuticals, Inc.	CI
01/24/01	Disclosure Statement Approved on Interim Basis for Infinity Pharmaceuticals, Inc.	CI
26/24/26	First Motion for Exclusivity Period Extension Filed by Infinity Pharmaceuticals, Inc.	CI
11/24/11	Joint Liquidation Plan and Disclsoure Statement Filed by Infinity Pharmaceuticals, Inc.	CI
08/24/08	Motion for Asset Sale Approved for Infinity Pharmaceuticals, Inc.	CI
23/23/23	Bidding Procedure Approved for Infinity Pharmaceuticals, Inc.	CI
02/23/02	Motion for Joint Administration Approved for Infinity Pharmaceuticals, Inc.	CI
30/23/30	Infinity Pharmaceuticals, Inc. Announces Resignation of Adelene Perkins from the Board	CI
29/23/29	INFINITY PHARMACEUTICALS LISTS BOTH ESTIMATED ASSETS AND LIABILI…	RE

24/23/24	Piper Sandler Downgrades Infinity Pharmaceuticals to Neutral From Overweight, Adjusts Price Target to $0.30 From $3	MT
15/22/15	B. Riley Downgrades Infinity Pharmaceuticals to Neutral From Buy, Lowers PT to $1.50 From $3; Moves to Sidelines Until Partner Helps Advance Eganelisib	MT
15/22/15	JonesTrading Downgrades Infinity Pharmaceuticals to Hold From Buy	MT
10/22/10	B. Riley Lowers Infinity Pharmaceuticals' Price Target to $3 from $5 to Reflect Delay in Eganelisib's Development, Uncertainty on Timing of Partnership; Maintains Buy Rating	MT
23/22/23	Piper Sandler Adjusts Infinity Pharmaceuticals' Price Target to $3 from $4, Keeps Overweight Rating	MT

Infinity Pharmaceuticals, Inc. Share Price

Stocks

INFI.Q

US45665G3039

Environmental Services & Equipment

Valuation: Infinity Pharmaceuticals, Inc.

Chart: Infinity Pharmaceuticals, Inc.

Latest news : Infinity Pharmaceuticals, Inc.

Analysts' recommendations: Infinity Pharmaceuticals, Inc.

Press Releases: Infinity Pharmaceuticals, Inc.

News in other languages: Infinity Pharmaceuticals, Inc.

Course Extremes

Latest insider transactions

Other Environmental Services & Equipment

Financials

Company Profile

Quotes

14/24/14	Triple Negative Breast Cancer Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)	AQ
05/23/05	Triple Negative Breast Cancer Pipeline, FDA Approvals, Clinical Trials Assessment, Companies 2023 \| Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., and others.	AQ
30/23/30	Infinity Pharmaceuticals : Bankruptcy - Form 8-K	PU
19/23/19	INFINITY ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Infinity Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm	BU
26/23/26	Infinity Pharmaceuticals Announces Value Preservation and Maximization Plan	BU

08/15/08	BIND Therapeutics : Les valeurs à suivre sur les marchés américains.
08/15/08	USA-Les valeurs à suivre à Wall Street

Date	Insider	Type	Main position	Quantity	% Market Cap.
08/23/08	Adelene Perkins	Fiscal year	Chief Executive Officer	19,46,462	2.1446%
02/22/02	Stéphane Peluso	Fiscal year	Chief Technology Officer	1,14,994	0.1290%
16/22/16	Samuel Agresta	Free	Chief Technology Officer	45,000	0.0505%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INFINITY PHARMACEUTICALS, INC.	0.00%	0.00%	-	-100.00%	90
WASTE MANAGEMENT, INC.	+0.42%	-0.17%	-7.22%	+35.06%	8.79TCr
REPUBLIC SERVICES, INC.	+0.38%	-0.53%	-17.04%	+45.32%	6.4TCr
VERALTO CORPORATION	+1.04%	-3.04%	-15.51%	-	2.03TCr
CLEAN HARBORS, INC.	+0.21%	+1.66%	+26.48%	+82.55%	1.52TCr
TETRA TECH, INC.	+1.88%	+2.47%	-21.13%	-8.78%	724.59Cr
FOMENTO DE CONSTRUCCIONES Y CONTRATAS, S.A.	+0.17%	+0.17%	-6.25%	+27.17%	633.28Cr
KURITA WATER INDUSTRIES LTD.	+3.18%	-5.16%	+57.66%	+45.03%	554.02Cr
INFORE ENVIRONMENT TECHNOLOGY GROUP CO., LTD.	+0.10%	-10.94%	+47.23%	+97.39%	473.07Cr
FUJIAN LONGKING CO., LTD.	+3.85%	+3.41%	+46.60%	+2.98%	309.87Cr
Average	+1.14%	-1.10%	+12.31%	+25.19%	2.14TCr
Weighted average by Cap.	+0.68%	-0.54%	-5.34%	+41.55%

	2021	2022
Net sales	18.58L 16.12L 14.86L 13.93L 26.02L 18Cr 26.56L 1.77Cr 68.64L 8.58Cr 69.75L 68.25L 30Cr	25.93L 22.5L 20.74L 19.44L 36.31L 25Cr 37.07L 2.47Cr 95.8L 12Cr 97.34L 95.24L 42Cr
Net income	-4.53Cr -3.93Cr -3.62Cr -3.39Cr -6.34Cr -433.39Cr -6.47Cr -43Cr -17Cr -208.91Cr -17Cr -17Cr -726.37Cr	-4.44Cr -3.85Cr -3.55Cr -3.33Cr -6.21Cr -424.84Cr -6.34Cr -42Cr -16Cr -204.78Cr -17Cr -16Cr -712.04Cr
Net Debt	-2.97Cr -2.57Cr -2.37Cr -2.22Cr -4.15Cr -284.06Cr -4.24Cr -28Cr -11Cr -136.92Cr -11Cr -11Cr -476.09Cr	1.1Cr 95.76L 88.27L 82.71L 1.55Cr 105.66Cr 1.58Cr 11Cr 4.08Cr 51Cr 4.14Cr 4.05Cr 177.09Cr

Current year	0		0
1 year	0		0
3 years	0		0.26
5 years	0		3.89
10 years	0		5.98